Wolfgang Schütte

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto et al. · The Lancet Oncology · 2019 · 613 citations · Full text

Medicine, Oncology, Pharmacology +12

Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer

Joachim von Pawel, Robert M. Jotte, David R. Spigel et al. · Journal of Clinical Oncology · 2014 · 344 citations · Full text

Medicine, Oncology, Pharmacology +13

FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia

Donald E. Low, Thomas M. File, Paul B. Eckburg et al. · Journal of Antimicrobial Chemotherapy · 2011 · 185 citations

Pharmacy, Pharmacology, Pharmacotherapy +13

Regulatory T cells with reduced repressor capacities are extensively amplified in pulmonary sarcoid lesions and sustain granuloma formation

Gunter Rappl, Stefan Pabst, Dagmar Riemann et al. · Clinical Immunology · 2011 · 81 citations

Life Sciences, Immunology, Pathology +17

KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)

Martin Sebastian, Wilfried Eberhardt, Petra Hoffknecht et al. · Lung Cancer · 2021 · 79 citations · Full text

Medicine, Genetics, Oncology +16